These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 37567878)

  • 1. Real-world experience with ponatinib therapy in chronic phase chronic myeloid leukemia: impact of depth of response on survival and prior exposure to nilotinib on arterial occlusive events.
    Abdelmagid MG; Al-Kali A; Litzow MR; Begna KH; Hogan WJ; Patnaik MS; Hashmi SK; Elliott MA; Alkhateeb H; Karrar OS; Fleti F; Elnayir MH; Rivera CE; Murthy HS; Foran JM; Kharfan-Dabaja MA; Badar T; Viswanatha DS; Reichard KK; Gangat N; Tefferi A
    Blood Cancer J; 2023 Aug; 13(1):122. PubMed ID: 37567878
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial.
    Cortes JE; Kim DW; Pinilla-Ibarz J; le Coutre PD; Paquette R; Chuah C; Nicolini FE; Apperley JF; Khoury HJ; Talpaz M; DeAngelo DJ; Abruzzese E; Rea D; Baccarani M; Müller MC; Gambacorti-Passerini C; Lustgarten S; Rivera VM; Haluska FG; Guilhot F; Deininger MW; Hochhaus A; Hughes TP; Shah NP; Kantarjian HM
    Blood; 2018 Jul; 132(4):393-404. PubMed ID: 29567798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Matching-adjusted indirect comparison of asciminib versus other treatments in chronic-phase chronic myeloid leukemia after failure of two prior tyrosine kinase inhibitors.
    Atallah E; Mauro MJ; Hochhaus A; Boquimpani C; Minami Y; Maheshwari VK; Saini L; Corbin R; Réa D
    J Cancer Res Clin Oncol; 2023 Aug; 149(9):6247-6262. PubMed ID: 36707445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-Term Follow-Up in Patients With Chronic Myeloid Leukemia Treated With Ponatinib in a Real-World Cohort: Safety and Efficacy Analysis.
    Mela Osorio MJ; Moiraghi B; Osycka MV; Pavlovsky MA; Varela AI; Bendek Del Prete GE; Tosin MF; Pérez MA; Riva ME; Berrios RR; Fernández I; Sackmann Massa F; Giere I; Sighel C; Pavlovsky C
    Clin Lymphoma Myeloma Leuk; 2024 Mar; 24(3):158-164. PubMed ID: 37973457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ponatinib: A new tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Shamroe CL; Comeau JM
    Ann Pharmacother; 2013 Nov; 47(11):1540-6. PubMed ID: 24265264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart.
    Caocci G; Mulas O; Abruzzese E; Luciano L; Iurlo A; Attolico I; Castagnetti F; Galimberti S; Sgherza N; Bonifacio M; Annunziata M; Gozzini A; Orlandi EM; Stagno F; Binotto G; Pregno P; Fozza C; Trawinska MM; De Gregorio F; Cattaneo D; Albano F; Gugliotta G; Baratè C; Scaffidi L; Elena C; Pirillo F; Scalzulli E; La Nasa G; Foà R; Breccia M
    Hematol Oncol; 2019 Aug; 37(3):296-302. PubMed ID: 30892724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up.
    Garg RJ; Kantarjian H; O'Brien S; Quintás-Cardama A; Faderl S; Estrov Z; Cortes J
    Blood; 2009 Nov; 114(20):4361-8. PubMed ID: 19729517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia: systematic reviews and economic analyses.
    Pavey T; Hoyle M; Ciani O; Crathorne L; Jones-Hughes T; Cooper C; Osipenko L; Venkatachalam M; Rudin C; Ukoumunne O; Garside R; Anderson R
    Health Technol Assess; 2012; 16(42):iii-iv, 1-277. PubMed ID: 23134589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Evaluation of impact of baseline ABL kinase domain point mutations on response to nilotinib in imatinib-resistant or-intolerant patients with chronic myeloid leukemia].
    Jiang H; Chen SS; Jiang B; Jiang Q; Qin YZ; Lai YY; Liu YR; Huang XJ
    Zhonghua Xue Ye Xue Za Zhi; 2012 Feb; 33(2):123-6. PubMed ID: 22730663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The new Systematic Coronary Risk Evaluation (SCORE2 and SCORE2-OP) estimates the risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib or ponatinib.
    Mulas O; Abruzzese E; Luciano L; Iurlo A; Attolico I; Castagnetti F; Galimberti S; Bonifacio M; Annunziata M; Gozzini A; Orlandi EM; Stagno F; Binotto G; Pregno P; Fozza C; Loi M; Trawinska MM; De Gregorio F; Cattaneo D; Albano F; Iezza M; Baratè C; Scaffidi L; Elena C; Giai V; Scalzulli E; Breccia M; La Nasa G; Caocci G
    Ann Hematol; 2024 Feb; 103(2):427-436. PubMed ID: 38012435
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ponatinib: a review of its use in adults with chronic myeloid leukaemia or Philadelphia chromosome-positive acute lymphoblastic leukaemia.
    Hoy SM
    Drugs; 2014 May; 74(7):793-806. PubMed ID: 24807266
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Life after ponatinib failure: outcomes of chronic and accelerated phase CML patients who discontinued ponatinib in the salvage setting.
    Boddu P; Shah AR; Borthakur G; Verstovsek S; Garcia-Manero G; Daver N; Kadia T; Ravandi F; Jain N; Alhuraiji A; Burger J; Kornblau S; Pierce S; Dellasala S; Jabbour E; Kantarjian H; Cortes J
    Leuk Lymphoma; 2018 Jun; 59(6):1312-1322. PubMed ID: 28972430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase.
    Hughes T; Saglio G; Branford S; Soverini S; Kim DW; Müller MC; Martinelli G; Cortes J; Beppu L; Gottardi E; Kim D; Erben P; Shou Y; Haque A; Gallagher N; Radich J; Hochhaus A
    J Clin Oncol; 2009 Sep; 27(25):4204-10. PubMed ID: 19652056
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Comparison of nilotinib
    Yu L; Qin YZ; Lai YY; Shi HX; Huang XJ; Hou Y; Jiang Q
    Zhonghua Xue Ye Xue Za Zhi; 2019 Dec; 40(12):996-1002. PubMed ID: 32023729
    [No Abstract]   [Full Text] [Related]  

  • 15. Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials.
    Jabbour E; Apperley J; Cortes J; Rea D; Deininger M; Abruzzese E; Chuah C; DeAngelo DJ; Hochhaus A; Lipton JH; Mauro M; Nicolini F; Pinilla-Ibarz J; Rosti G; Rousselot P; Shah NP; Talpaz M; Vorog A; Ren X; Kantarjian H
    Leukemia; 2024 Mar; 38(3):475-481. PubMed ID: 38287132
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial.
    Cortes J; Apperley J; Lomaia E; Moiraghi B; Undurraga Sutton M; Pavlovsky C; Chuah C; Sacha T; Lipton JH; Schiffer CA; McCloskey J; Hochhaus A; Rousselot P; Rosti G; de Lavallade H; Turkina A; Rojas C; Arthur CK; Maness L; Talpaz M; Mauro M; Hall T; Lu V; Srivastava S; Deininger M
    Blood; 2021 Nov; 138(21):2042-2050. PubMed ID: 34407543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical outcomes in patients with Philadelphia chromosome-positive leukemia treated with ponatinib in routine clinical practice-data from a Belgian registry.
    Devos T; Havelange V; Theunissen K; Meers S; Benghiat FS; Gadisseur A; Vanstraelen G; Vellemans H; Bailly B; Granacher N; Lewalle P; De Becker A; Van Eygen K; Janssen M; Triffet A; Vrelust I; Deeren D; Mazure D; Bekaert J; Beck M; Selleslag D
    Ann Hematol; 2021 Jul; 100(7):1723-1732. PubMed ID: 33942128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world outcomes of ponatinib treatment in 724 patients with CML and Ph+ ALL: a post-marketing surveillance study with a special interest in arterial occlusive events in Japan.
    Takahashi N; Kondo T; Ikari Y; Fukumoto Y; Hatake K; Masunari A; Nishibayashi S; Kageyama A; Fukuta Y; Tojo A
    Jpn J Clin Oncol; 2024 Aug; 54(8):930-938. PubMed ID: 38747937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials.
    Jain P; Kantarjian H; Alattar ML; Jabbour E; Sasaki K; Nogueras Gonzalez G; Dellasala S; Pierce S; Verstovsek S; Wierda W; Borthakur G; Ravandi F; O'Brien S; Cortes J
    Lancet Haematol; 2015 Mar; 2(3):e118-28. PubMed ID: 26687797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative Effectiveness of Newer Tyrosine Kinase Inhibitors Versus Imatinib in the First-Line Treatment of Chronic-Phase Chronic Myeloid Leukemia Across Risk Groups: A Systematic Review and Meta-Analysis of Eight Randomized Trials.
    Yun S; Vincelette ND; Segar JM; Dong Y; Shen Y; Kim DW; Abraham I
    Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):e85-94. PubMed ID: 27101984
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.